Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy

Summary

While the association between cancer and symptomatic venous thromboembolism (VTE) is well established, the incidence and risk factors for incidental VTE in cancer patients remain unclear. The medical records of 1,921 consecutive cancer patients starting chemotherapy from January 2003 up to March 2009 were identified. Patients with a positive history of VTE were excluded. Pre-existing signs of VTE, kind and stage of malignancy, first and subsequent lines of chemotherapy, and all follow-up computed tomography (CT) scans were analysed. The primary outcome was incidental VTE. Overall, there were 101 (5.3%) VTE, 62 (3.2%) incidental and 39 (2.0%) symptomatic during a median of eight months (range 3–72). The incidence on CT scans was 0.58% (95%CI: 0.44–0.74). Incidental VTE included 24 pulmonary embolism, 28 deep venous thrombosis of the extremities, and 10 thromboses of the cava or splanchnic veins. Half of the incidental VTE occurred in the first 3–6 months of chemotherapy with a relatively higher incidence in gyneco-logical and lung cancers. The presence of metastases, high leukocyte count, and platin-based chemotherapy increased the risk up to threefold. All patients with incidental VTE regardless the location received half to full therapeutic doses of low-molecular-weight heparin for a minimum of three months. In summary, incidental VTE is a relative common finding in patients with solid tumours, especially in the first months of chemotherapy. Further research is needed to understand the natural history of incidental thrombosis in order to develop adequate management guidelines.

Keywords

Cancer - venous thrombosis - chemotherapy

• References

• 1 Lee AYY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003; 107: I-17-I-21.
• 2 Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005; 06: 401-410.
• 3 Seddighzadeh A, Shetty R, Goldhaber SZ. Venous thromboembolism in patients with active cancer. Thromb Haemost 2007; 98: 656-661.
• 4 Paneesha S, McManus A, Arya R. et al. VERITY Investigators.. Frequency, demographics and risk (according to tumour type or site) of cancer-associated thrombosis among patients seen at outpatient DVT clinics. Thromb Haemost 2010; 103: 338-343.
• 5 Sebastian AJ, Paddon AJ. Clinically unsuspected pulmonary embolism-an important secondary finding in oncology CT. Clin Radiol 2006; 61: 81-85.
• 6 Boswell WD, Pierce J, Fahimi A. et al. Incidental pulmonary emboli detected by multi-detector row spiral CT in cancer patients. Cancer Imag 2004; 04: S58.
• 7 Gosselin MV, Rubin GD, Leung AN. et al. Unsuspected Pulmonary embolism: prospective detection on routine helical CT Scans. Radiology 1998; 208: 209-215.
• 8 Gladish GW, Choe DH, Marom EM. et al. Incidental pulmonary emboli in oncology patients: prevalence, CT evaluation, and natural history. Radiology 2006; 240: 246-255.
• 9 Storto ML, Di Credico A, Guido F. et al. Incidental detection of pulmonary emboli on routine MDCT of the chest. Am J Roentgenol 2005; 184: 264-267.
• 10 Douma RA, Kok MGM, Verberne LM. et al. Incidental venous thromboembolism in cancer patients: prevalence and consequence. Thromb Res 2010; 125: 306-309.
• 11 Otten H-M, Mathijssen J, ten Cate H. et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy. An underestimated phenomenon. Arch Intern Med 2004; 164: 190-194.
• 12 Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res 2006; 118: 555-568.
• 13 Heidrich H, Konau E, Hesse P. Asymptomatic venous thrombosis in cancer patients, a problem often overlooked. Results of a retrospective and prospective study. Vasa 2009; 38: 160-166.
• 14 TNM Atlas. Illustrated guide to the TNM/pTNM Classification of Malignant Tumours/UICC. 4^th ed (corrected 2^nd ed). Berlin, Germany: Spinger-Verlag; 1999
• 15 Lyman GH, Khorana AA, Falanga A. et al. American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer. J Clin Oncol 2007; 25: 5490-5505.
• 16 Dentali F, Ageno W, Becattini C. et al. Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta-analysis. Thromb Res 2010; 125: 518-522.
• 17 Agnelli G, Gussoni G, Bianchini C. et al. on behalf of the PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009; 10: 943-949.
• 18 O’Connell CL, Boswell WD, Duddalwar V. et al. Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance. J Clin Oncol 2006; 24: 4928-4932.
• 19 Khorana AA, Kuderer NM, Culakova E. et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902-4907.
• 20 Chew HK, Wun T, Harvey D. et al. Incidence of venous thromboembolism and its effects on survival among patients with common cancers. Arch Intern Med 2006; 166: 458-464.
• 21 Blom JW, Doggen CJM, Osanto S. et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. J Am Med Assoc 2005; 293: 715-722.
• 22 Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002; 87: 575-579.
• 23 Blom JW, Vanderschoot JP, Oostindier MJ. et al. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 2006; 04: 529-535.
• 24 Trujillo-Santos J, Di Micco P, Iannuzzo M. et al. RIETE Investigators.. Elevated white blood cell count and outcome in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100: 905-911.
• 25 Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 2001; 358: 9-15.
• 26 Mismetti P, Laporte S, Darmon JY. et al. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001; 88: 913-930.
• 27 Vaitkus PT, Leizorovicz A, Cohen AT. et al. Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. Thromb Haemost 2005; 93: 76-79.
• 28 Dentali F, Vitale J, Nitti C. et al. Prognostic relevance of asymptomatic VTE in cancer patients. J Thromb Haemost 2009; 07 (Suppl. 02) Abstract.
• 29 Kearon C, Kahn SR, Agnelli G. et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 454-545.
• 30 Engelke C, Rummeny EJ, Marten K. Pulmonary embolism at multi-detector row CT of chest: one year survival of treated and untreated patients. Radiology 2006; 239: 563-575.